jRCT2031230257
Untitled Trial
A randomized, double blind, multicenter phase III study to evaluate the long term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.
ABIVAX S.A.·Japan Registry Clinical TrialRecruiting
Study focus
- Disease/Condition
- Ulcerative colitis
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- ABIVAX S.A.
- Location
- Argentina;Australia;Austria;Belgium;Bulgaria;Brazil;Canada;China;Czech;France;Germany;Greece;Hungary
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Ulcerative colitisOther ulcerative colitisUlcerative colitis, unspecifiedArthropathy in ulcerative colitisJuvenile arthritis in ulcerative colitis
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031230257
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031230257 through Pure Global AI's free database. This phase not specified trial is sponsored by ABIVAX S.A. and is currently Recruiting. The study focuses on Ulcerative colitis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.